- Home
- PLCE vs ABOS Comparison
PLCE vs ABOS Comparison
Compare PLCE & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLCE | ABOS |
|---|---|---|
| Founded | 1969 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.2M | 155.7M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLCE | ABOS |
|---|---|---|
| Price | $3.69 | $3.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.50 | ★ $7.50 |
| AVG Volume (30 Days) | 242.7K | ★ 277.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.34 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.65 | $0.86 |
| 52 Week High | $9.56 | $3.50 |
Technical Indicators
Market Signals| Indicator | PLCE | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 65.35 |
| Support Level | N/A | $1.21 |
| Resistance Level | $4.79 | N/A |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 5.53 | 80.79 |
Price Performance
Historical ComparisonAbout PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.